Back To White Oak: US FDA Adcomms Go Fully In-Person, Starting With Antimicrobials Panel

 
• By Sue Sutter

The 9 September meeting on Iterum Therapeutics' oral sulopenem product for uncomplicated urinary tract infections marks the first fully in-person advisory committee drug review since the COVID-19 pandemic hit in early 2020.

School bus
Like children returning to school, advisory committee members and public speakers will be returning to the FDA's White Oak headquarters in September. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers